(VIANEWS) – LUMIBIRD (LBIRD.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LUMIBIRD (LBIRD.PA) | €11.90 | 1.25% | 5.68% |
| VETOQUINOL (VETO.PA) | €103.00 | 1.02% | 12.13% |
| SARTORIUS STED BIO (DIM.PA) | €246.10 | 0.59% | 18.66% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LUMIBIRD (LBIRD.PA)
1.25% Forward Dividend Yield and 5.68% Return On Equity
Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two segments, Photonics and Medical. The company offers solid-state and diode lasers, fiber lasers, fiber lasers/amplifiers and components, Laser rangefinder and LiDAR wind doppler LiDAR, medical and ophthalmological equipment. Its products are used in various applications, such as industrial and scientific, defense and space, and lidar sensors. The company was incorporated in 1970 and is headquartered in Lannion, France.
Earnings Per Share
As for profitability, LUMIBIRD has a trailing twelve months EPS of €0.45.
PE Ratio
LUMIBIRD has a trailing twelve months price to earnings ratio of 26.44. Meaning, the purchaser of the share is investing €26.44 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.68%.
More news about LUMIBIRD.
2. VETOQUINOL (VETO.PA)
1.02% Forward Dividend Yield and 12.13% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.97.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 20.72. Meaning, the purchaser of the share is investing €20.72 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.13%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VETOQUINOL’s stock is considered to be overbought (>=80).
Moving Average
VETOQUINOL’s worth is way above its 50-day moving average of €83.09 and way higher than its 200-day moving average of €86.42.
Volatility
VETOQUINOL’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.30%, a positive 0.22%, and a positive 1.44%.
VETOQUINOL’s highest amplitude of average volatility was 1.74% (last week), 1.76% (last month), and 1.44% (last quarter).
Yearly Top and Bottom Value
VETOQUINOL’s stock is valued at €103.00 at 06:30 EST, higher than its 52-week high of €98.60.
More news about VETOQUINOL.
3. SARTORIUS STED BIO (DIM.PA)
0.59% Forward Dividend Yield and 18.66% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €4.99.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 49.32. Meaning, the purchaser of the share is investing €49.32 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
More news about SARTORIUS STED BIO.
